Sign in
Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of Great Than or Equal to 4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Annual Meeting Talks
2019
Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: One-Year Primary Outcomes From the Randomized RECOVERY Trial
Charles C Wykoff, MD, PhD, FASRS
What Happens to Diabetic Retinopathy Severity Scores With Less Aggressive Treatment? A Post Hoc Analysis of the RISE and RIDE Open Label Extension Study
Roger A. Goldberg, MD, MBA
Category: wet AMD